Instead, the tumors are accompanied by an immune-tolerogenic TME, enriched with PD-L1-expressing inflammatory cells and TIM-3-positive T cells, showing similarity to DLBCL in immune-privileged sites with microenvironmental PD-L1 expression in immune-competent patients [159]. Here, CD274 is linked to diffuse large B-cell lymphoma.